Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multicenter, Randomized, Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury

NCT00810940 is registered in ClinicalTrials.gov with Abela Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00810940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00810940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multicenter, Randomized, Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury
Lead sponsor
Abela Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2010
Completion date
December 31, 2011
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

severe head trauma